These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29970544)

  • 1. Hybrid Imaging PET/CT with Application of
    Baxa J; Ferda J; Ferdova E; Vojtisek R; Topolcan O; Finek J
    Anticancer Res; 2018 Jul; 38(7):4153-4157. PubMed ID: 29970544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice.
    Yue JB; Yang J; Liu J; Lee J; Cabrera AR; Sun XD; Bai GH; Li YH; Yu JM
    Radiother Oncol; 2014 Jun; 111(3):475-81. PubMed ID: 24813091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.
    Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH
    J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
    J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
    Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
    J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas.
    van Egmond SL; Piscaer V; Janssen LM; Stegeman I; Hobbelink MG; Grolman W; Terhaard CH
    Acta Oncol; 2016; 55(9-10):1099-1106. PubMed ID: 27219720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma.
    Chatterjee A; Gupta T; Rangarajan V; Purandare N; Kunder S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal J
    Nucl Med Commun; 2018 Sep; 39(9):859-864. PubMed ID: 29939883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
    Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
    Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.
    Arens AI; Troost EG; Hoeben BA; Grootjans W; Lee JA; Grégoire V; Hatt M; Visvikis D; Bussink J; Oyen WJ; Kaanders JH; Visser EP
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):915-24. PubMed ID: 24346414
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.
    Cacicedo J; Navarro A; Del Hoyo O; Gomez-Iturriaga A; Alongi F; Medina JA; Elicin O; Skanjeti A; Giammarile F; Bilbao P; Casquero F; de Bari B; Dal Pra A
    Br J Radiol; 2016 Nov; 89(1067):20160217. PubMed ID: 27416996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up].
    Hideghéty K; Cserháti A; Besenyi Z; Zag L; Gaál S; Együd Z; Mózes P; Szántó E; Csenki M; Rusz O; Varga Z; Dobi Á; Maráz A; Pávics L; Lengyel Z
    Magy Onkol; 2015 Jun; 59(2):103-10. PubMed ID: 26035157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of
    Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
    Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.